Tag: GlobeNewswire

Study confirms established road-haulage capacity up to 11.5 wet Mtpa on both bauxite export routes: north to Port of Enseada, or south to a potential load-out for FIOL rail-linked expansion option

SYDNEY, Oct. 05, 2026 (GLOBE NEWSWIRE) —

Highlights

Independent support of base case, plus growth options: Independent road-logistics study confirmed road haulage as viable at all tested capacities, up to 11.5 wet Mtpa – twice the Scoping Study base case of 5.75 wet Mtpa (5 Mtpa dry) – with suitable service levels and no modelled road-capacity constraints identified.

Direct road haulage to Enseada. The bauxite haulage route uses the BR-101 federal highway, approximately 160 km from the North District and 220 km from the Central District.

Modest share of total road corridor traffic: Alurion trucks are expected to represent less than 1% of total vehicles at 5.75 Mtpa, rising to 1.6% at 11.5 Mtpa.

Enseada port expansion offers a pathway to increased project scale: Alurion is advancing engineering work to assess options for expanding Enseada’s port capacity up to 13.5 wet Mtpa, in collaboration with the port operator. The PFS will integrate this work with the road-haulage findings to assess the technical and commercial feasibility of increased project scale.

Further growth potential via FIOL Rail & Porto Sul integration: The study confirmed that the established road route of less than 90 km from the Central District to a proposed FIOL rail load-out could support haulage of up to 11.5 wet Mtpa, with appropriate service levels and no road-capacity constraints.

Road haulage capacity confirmed ahead of the PFS: Route, network capacity and fleet parameters will underpin the Amargosa direct-ship bauxite PFS targeted for mid-2027. This is the first of the sequenced PFS workstreams to complete, with drilling, trenching and metallurgical programs scheduled from Q4 2026 onwards.

CEO comment

“The study provides independent validation for the road-capacity assumptions in Amargosa’s development planning. It gives the PFS a defined route and fleet configuration, with no modelled road-capacity constraints under any of the three haulage scenarios assessed.

Our base case remains road haulage to Enseada. The PFS will test whether higher volumes and modular port expansion can improve project economics and justify the additional investment.

The southern connection adds a longer-term opportunity to develop more of Amargosa’s resource base, potentially with less dedicated infrastructure. That option depends on completion of FIOL and Porto Sul and securing commercial access, while our Enseada base case can advance independently.”

Maurício Noronha
Chief Executive Officer, Alurion Resources

Independent road-haulage study overview

Alurion Resources Limited (ASX: ALU) commissioned Engimind, a specialist transport-engineering consultancy, to independently assess the Bahia public road network between Amargosa and the Port of Enseada to support a range of potential bauxite export volumes.

The study also assessed the southern route from the Central District to a proposed FIOL rail load-out and evaluated the fleet and operating configurations required for both routes. Three haulage scenarios were assessed: the Scoping Study base case of 5.75 wet Mtpa, plus 8.6 and 11.5 wet Mtpa.

To test these volumes, Engimind measured existing road traffic, projected its future growth and added Amargosa’s truck movements under each scenario to assess road performance over the modelled operating period. The study also simulated the full haulage cycle and loading-yard operations to assess fleet requirements, turnaround times and terminal capacity.

Road to Enseada supports twice the base-case capacity

The study supports Amargosa’s base-case strategy of road haulage to Enseada, confirming acceptable modelled service levels and no road-capacity constraints at volumes up to 11.5 wet Mtpa – double the Scoping Study base case of 5.75 wet Mtpa. This provides independent support for the planned export route and a basis to evaluate increased project scale.

The preferred routes connect the North and Central bauxite districts to the Port of Enseada mostly via the BR-101 federal highway, over distances of approximately 160 km and 220 km, respectively. This development pathway uses the established highway network, supplemented by targeted local access-road upgrades and district loading terminals.

Engimind identified a preferred seven-axle truck configuration with a gross combination weight of 59 tonnes, providing a defined basis for PFS fleet sizing and operating-cost estimates. Loading terminals in each district are planned to support dispatch, with terminal site selection under way. Mine-to-port logistics capital is expected to include the haulage fleet, district terminals and access-road works, with estimates to be updated in the PFS.

The PFS will integrate these route and fleet parameters with terminal designs and Enseada port configurations to assess the technical and commercial feasibility of higher export volumes.

Figure 1: Northern Route Overview

Enseada port expansion offers a pathway to higher export volumes

Alurion has been actively engaging with the Enseada port operator to assess the road-haulage interface, stockyard handling, port services and offshore transshipment. The Scoping Study was based on bauxite exports of 5 Mtpa on a dry basis, equivalent to the 5.75 wet Mtpa road-haulage case.

Alurion is leading engineering studies, with input from the port operator, to define the port configurations that could lift Enseada’s export capacity to up to 13.5 wet Mtpa. The outcomes will be incorporated into the PFS and assessed alongside the higher haulage volumes supported by the road study, to determine the technical and commercial feasibility of a larger-scale operation.

Southern road connection supports a future FIOL–Porto Sul export option

The study also validated the southern road haulage route from Central District to the site of a proposed FIOL rail load-out. This 86km southern road haulage connection to FIOL links an important large-scale bauxite export option which will be assessed once construction of the high-capacity FIOL-Porto Sul rail and port infrastructure chain restarts.

Figure 2: Southern Route Overview

The FIOL-Porto Sul corridor offers a potential longer-term pathway to increase Amargosa’s export scale. With indicative design capacities of approximately 60 Mtpa for FIOL rail and 40 Mtpa for Porto Sul, the proposed infrastructure could support a larger operation incorporating Amargosa’s substantial beneficiable bauxite resources.

The new road-haulage findings support evaluation of a connection to FIOL that could avoid the approximately 40 km dedicated rail spur envisaged in the Scoping Study, potentially reducing both infrastructure requirements and the capital intensity of future expansion.

Further assessment of this option will follow the restart of construction of the FIOL-Porto Sul infrastructure. Development remains dependent on completion of FIOL and Porto Sul and securing commercial access, while road haulage to Enseada remains Amargosa’s base-case development pathway.

Figure 3: FIOL Rail (70% Complete), Porto Sul (Design)

Next milestones

The road haulage study feeds into the Amargosa mine planning, scheduling and the PFS commercial workstreams. The remaining programs will provide geological, product and metallurgical inputs, with results expected to be reported as each program is completed. The PFS remains on-track for completion in mid-2027.

This announcement has been authorised for release by the Chief Executive Officer.

For further information and enquiries please contact:

Maurício Noronha

Chief Executive Officer

Alurion Resources Limited

mauricio.noronha@alurionresources.com

About Engimind

Engimind is a specialist mobility and transport-engineering consultancy established in 2006, with offices in Lisbon and São Paulo and more than 3,000 projects completed across Europe, Latin America and Africa. Its track record includes the Salvador BRT system in Bahia, traffic and capacity studies for national road-concession and logistics-platform programs in Portugal, and studies supporting the New Lisbon Airport, with specialist capabilities in traffic engineering and HCM capacity analysis.

The study was prepared under the direction of André Remédio, Director and Managing Partner of Engimind and Engimind Brasil. Mr Remédio holds a Master’s degree in Transport and a degree in Civil Engineering (Planning, Management and Transport) from Instituto Superior Técnico, University of Lisbon, and is a registered professional engineer with the Ordem dos Engenheiros (Portugal) and CONFEA/CREA-SP (Brazil). He has more than 25 years’ experience in traffic engineering, road-capacity analysis and transport modelling, including traffic studies for Brazilian federal highways such as the BR-101, BR-116, BR-040 and BR-153. Engimind is independent of Alurion, and its fees for the study are not contingent on the study’s conclusions or outcome.

Cautionary Statement — Scoping Study

References in this announcement to the Amargosa Scoping Study are references to the Amargosa Scoping Study as set out in the Independent Technical Assessment Report (ITAR) in Alurion’s Prospectus dated 5 June 2026 and the Supplemental Prospectus dated 19 June 2026. The Scoping Study is a preliminary technical and economic assessment prepared to an intended accuracy of ±35% and is based on low level technical and economic assessments that are insufficient to support the estimation of Ore Reserves or to provide assurance of an economic development case at this stage. The Production Target evaluated in that study comprises approximately 89% Indicated Mineral Resources and 11% Inferred Mineral Resources. Inferred Mineral Resources are considered too speculative geologically to apply Modifying Factors in sufficient detail to support the estimation of Ore Reserves, and there is no certainty that the Production Target, or the forecast economic outcomes derived from it, will be realised. Investors should not make investment decisions based solely on the results of the Scoping Study.

The programs described in this announcement are exploration, metallurgical and study activities. No Ore Reserve has been estimated for Amargosa, and no assurance can be given that the drilling, trenching or test work programs will achieve the objectives described, that Mineral Resources will be upgraded to higher confidence categories, that improved beneficiation yields or critical mineral recoveries will be demonstrated, or that a Definitive Feasibility Study will support development of the Project. Development of the Project, if it proceeds, will require additional funding, and there is no certainty that such funding will be available when required or on acceptable terms.

References in this announcement to haulage volumes of 5.75 wet Mtpa, 8.625 wet Mtpa and 11.5 wet Mtpa are road-logistics capacity assessment scenarios evaluated by the independent study. They describe the assessed capacity of the road network and haulage fleet configurations and are not production targets, production forecasts or statements of intent. The same applies to references to potential Port of Enseada export capacity of up to 13.5 wet Mtpa, which is the subject of engineering studies in progress. The only Production Target evaluated for Amargosa remains that set out in the Scoping Study referred to above, and there is no certainty that any production rate will be achieved. References in this announcement to FIOL and Porto Sul, including any indicative rail or port capacities, relate to proposed third-party infrastructure that is not owned or controlled by Alurion and has not been completed. Alurion holds no rights, access entitlement or capacity allocation in respect of that infrastructure and has not entered into any agreement in relation to it. There is no certainty that the infrastructure will be completed, or completed on any particular timing, capacity, cost or commercial terms, and no assurance that Alurion would be able to access it. Any capacity figures referred to are drawn from publicly available third-party sources and have not been independently verified by Alurion. The southern route is a possible upside pathway only; Alurion’s base-case development pathway is road haulage to the Port of Enseada and does not depend on FIOL or Porto Sul. The Port of Enseada is a third-party facility, and binding port access and any capacity expansion remain subject to commercial agreement with the port operator.

Forward-Looking Statements and Information

This Announcement may contain “forward-looking statements” and “forward-looking information”, including statements and forecasts which include (without limitation) expectations regarding industry growth and other trend projections, forward-looking statements about the Amargosa Project, future strategies, results and outlook of ALU and the opportunities available to ALU. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “is expecting”, “budget”, “outlook”, “scheduled”, “target”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes”, or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might”, or “will” be taken, occur or be achieved. Such information is based on assumptions and judgments of ALU regarding future events and results. Readers are cautioned that forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, targets, performance or achievements of ALU to be materially different from any future results, targets, performance or achievements expressed or implied by the forward-looking information.

Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, the Directors and management of the Company. These and other factors could cause actual results to differ materially from those expressed in any forward-looking statements.

Forward-looking information and statements are (further to the above) based on the reasonable assumptions, estimates, analysis and opinions of ALU made in light of its perception of trends, current conditions and expected developments, as well as other factors that ALU believes to be relevant and reasonable in the circumstances at the date such statements are made, but which may prove to be incorrect. Although ALU believes that the assumptions and expectations reflected in such forward-looking statements and information (including as described in this Announcement) are reasonable, readers are cautioned that this is not exhaustive of all factors which may impact on the forward-looking information.

The Company cannot and does not give assurances that the results, performance or achievements expressed or implied in the forward-looking information or statements detailed in this Announcement will occur and prospective investors are cautioned not to place undue reliance on these forward-looking information or statements.

Competent Persons Statement

The information in this announcement that relates to the Amargosa Mineral Resource Estimate and the Amargosa Scoping Study is extracted from the Independent Technical Assessment Report (ITAR) in Alurion’s Prospectus dated 5 June 2026 and the Supplemental Prospectus dated 19 June 2026 (“Prospectus Reports”), which are available to view at https://www.alurionresources.com/. Alurion confirms that: (a) it is not aware of any new information or data that materially affects the information included in the Prospectus Reports; (b) all material assumptions and technical parameters underpinning the Mineral Resource Estimate and the Production Target, and the forecast financial information derived from the Production Target, in the Prospectus Reports continue to apply and have not materially changed; and (c) the form and context in which the relevant Competent Persons’ findings are presented in this announcement have not been materially changed from the Prospectus Reports. No new Exploration Results, Mineral Resources or Ore Reserves are reported in this announcement.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/550fa021-36f1-4acb-acee-557c2ac3171d

https://www.globenewswire.com/NewsRoom/AttachmentNg/ddfa99bc-424c-4259-ae52-d5df736670b4

https://www.globenewswire.com/NewsRoom/AttachmentNg/6d4a64a2-f410-4b88-8fc4-03071495d397

GUANGZHOU, China, Oct. 05, 2026 (GLOBE NEWSWIRE) — YSX TECH. CO., LTD (NASDAQ: “YSXT”) (the “Company”), a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China, today announced that it will hold an extraordinary general meeting of shareholders (the “EGM”), on October 19, 2026 at 12:00 a.m. Eastern Time, at Room 102, Building 1, No. 22, Huazhou Road, Haizhu District, Guangzhou, Guangdong, China , for the purpose of considering and voting on the following proposals:

1. To approve, as an ordinary resolution, that the Company’s authorized share capital be increased, effective immediately, from US$50,000 divided into (i) 470,000,000 Class A ordinary shares of US$0.0001 par value each and (ii) 30,000,000 Class B ordinary shares of US$0.0001 par value each, to US$220,000,000 divided into (i) 2,000,000,000,000 Class A ordinary shares of US$0.0001 par value each and (ii) 200,000,000,000 Class B ordinary shares of US$0.0001 par value each, by the creation and addition of 1,999,530,000,000 authorised but unissued Class A ordinary shares of US$0.0001 par value each and 199,970,000,000 authorized but unissued Class B ordinary shares of US$0.0001 par value each (the “Authorized Share Capital Increase”).
2. To approve, as a special resolution, that the notice period to members for convening general meetings from fourteen (14) clear days in the case of an annual general meeting and seven (7) clear days in the case of any general meeting other than an annual general meeting, to five (5) clear days for all general meetings (the “Reduction of Notice Period”).
3. To approve, as a special resolution, that, subject to and immediately following the Authorized Share Capital Increase being effected, the Company adopt an amended and restated memorandum and articles of association, the form of which is attached to the notice of the Meeting as the Appendix in substitution for, and to the exclusion of, the Company’s existing memorandum and articles of association, to reflect, among other things, the Authorized Share Capital Increase, the Reduction of Notice Period and certain housekeeping changes.

The Board of Directors has fixed the close of business on September 30, 2026 as the record date (the “Record Date”) for determining the shareholders entitled to receive notice of and to vote at the EGM or any adjournment thereof. Only the shareholders on the Record Date are entitled to receive notice of and to vote at the EGM or any adjournment thereof.

Shareholders may obtain a copy of the proxy materials from the Company’s website at https://ir.ysxtechcay.com/. The notice of the EGM, the proxy statement, and the proxy card were sent or made available to shareholders on October 2, 2026.

About YSX TECH. CO., LTD

YSX TECH. CO., LTD is a Cayman Islands exempted company that, through its variable interest entities in China, provides comprehensive business solutions mainly for insurance companies and brokerages in China. The Company possesses in-depth knowledge of the Chinese insurance industry accumulated from years of servicing customers, and specializes in auto insurance aftermarket value-added services, software development and information technology services, as well as other scenario-based customized services, such as products and customer development services. For more information please visit: https://ir.ysxtechcay.com and https://www.ysxnet.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the Company’s filings with the United States Securities and Exchange Commission, which are available for review at www.sec.gov. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
YSX Tech. Co., Ltd
marketing@ysxnet.com
+86 (20) 2984 2002

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Blaize Holdings, Inc. (Nasdaq: BZAI; BZAIW) (“Blaize” or the “Company”), a leader in programmable, energy-efficient AI computing, today announced its preliminary third quarter 2026 revenue. The Company also provided an update regarding its previously issued full-year 2026 revenue guidance. These matters are further described in a Current Report on Form 8-K filed today with the U.S. Securities and Exchange Commission.

Preliminary Third Quarter 2026 Revenue and Full Year Outlook

The Company expects to report preliminary revenue of approximately $0.5 million for the third quarter ending September 30, 2026.

The Company’s preliminary third-quarter revenue estimate is based on currently available information and remains subject to completion of the Company’s quarter-end closing procedures. Actual results could differ materially from this preliminary estimate.

Given the foregoing and as noted below, the Company is revising its full-year revenue guidance for 2026 to be between $32.0 million and $36.0 million. The revised guidance is based on binding, non-cancellable purchase orders from NeoTensr and a new purchase order from an existing customer in process of signature. The product shipments to NeoTensr this quarter relate to the contract announced by the Company in April 2026 for up to $50.0 million. The revision reflects the Company’s updated expectations regarding shipment timing and management of working capital to meet inventory purchase needs. The Company has sufficient inventory on hand to partially fulfill the orders in the fourth quarter and is working with suppliers to obtain the balance before the year end. Any increased costs that are able to be passed through to customers or new customer commitments received during the fourth quarter that can be fulfilled through inventory on hand or software service agreements and recognized in the quarter would be additive to the Company’s revenue expectations. Should there be delays in timing or in receiving payments from customers scheduled during the fourth quarter, the Company’s revenue recognition for the year could be adversely affected.

About Blaize
Blaize delivers a programmable AI platform, purpose-built for AI inference workloads in real-world environments. Its Hybrid AI architecture combines the Blaize GSP (Graph Streaming Processor) with GPU-based infrastructure, enabling AI inference workloads to run across edge, cloud, and data center. Blaize solutions support computer vision, multimodal AI, and sensor-driven applications across smart cities, industrial automation, telecommunications, retail, logistics, and mission-critical operations. Blaize is headquartered in San Jose, California, with a presence across North America, Europe, the Middle East, and Asia. Visit www.blaize.com or follow us on LinkedIn @blaizeinc.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the Company’s preliminary estimated revenue for the three months ended September 30, 2026, and the Company’s guidance and expectations for the fourth quarter of 2026.

Forward-looking statements are based on management’s current expectations and are subject to risks, uncertainties and changes in circumstances, many of which are outside the Company’s control. Actual results may differ materially from those expressed or implied by these forward-looking statements. Important factors that could cause actual results to differ materially are discussed in the Company’s filings with the Securities and Exchange Commission, including the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, as amended on April 30, 2026. Forward-looking statements speak only as of the date of this press release, and the Company assumes no obligation to update them except as required by law.

Investors Contact
IR@blaize.com

Media Contact
press@blaize.com

SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) — Blaize Holdings, Inc. (Nasdaq: BZAI; BZAIW) (“Blaize” or the “Company”), a leader in programmable, energy-efficient AI computing, today announced its preliminary third quarter 2026 revenue. The Company also provided an update regarding its previously issued full-year 2026 revenue guidance. These matters are further described in a Current Report on Form 8-K filed today with the U.S. Securities and Exchange Commission.

Preliminary Third Quarter 2026 Revenue and Full Year Outlook

The Company expects to report preliminary revenue of approximately $0.5 million for the third quarter ending September 30, 2026.

The Company’s preliminary third-quarter revenue estimate is based on currently available information and remains subject to completion of the Company’s quarter-end closing procedures. Actual results could differ materially from this preliminary estimate.

Given the foregoing and as noted below, the Company is revising its full-year revenue guidance for 2026 to be between $32.0 million and $36.0 million. The revised guidance is based on binding, non-cancellable purchase orders from NeoTensr and a new purchase order from an existing customer in process of signature. The product shipments to NeoTensr this quarter relate to the contract announced by the Company in April 2026 for up to $50.0 million. The revision reflects the Company’s updated expectations regarding shipment timing and management of working capital to meet inventory purchase needs. The Company has sufficient inventory on hand to partially fulfill the orders in the fourth quarter and is working with suppliers to obtain the balance before the year end. Any increased costs that are able to be passed through to customers or new customer commitments received during the fourth quarter that can be fulfilled through inventory on hand or software service agreements and recognized in the quarter would be additive to the Company’s revenue expectations. Should there be delays in timing or in receiving payments from customers scheduled during the fourth quarter, the Company’s revenue recognition for the year could be adversely affected.

About Blaize
Blaize delivers a programmable AI platform, purpose-built for AI inference workloads in real-world environments. Its Hybrid AI architecture combines the Blaize GSP (Graph Streaming Processor) with GPU-based infrastructure, enabling AI inference workloads to run across edge, cloud, and data center. Blaize solutions support computer vision, multimodal AI, and sensor-driven applications across smart cities, industrial automation, telecommunications, retail, logistics, and mission-critical operations. Blaize is headquartered in San Jose, California, with a presence across North America, Europe, the Middle East, and Asia. Visit www.blaize.com or follow us on LinkedIn @blaizeinc.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements regarding the Company’s preliminary estimated revenue for the three months ended September 30, 2026, and the Company’s guidance and expectations for the fourth quarter of 2026.

Forward-looking statements are based on management’s current expectations and are subject to risks, uncertainties and changes in circumstances, many of which are outside the Company’s control. Actual results may differ materially from those expressed or implied by these forward-looking statements. Important factors that could cause actual results to differ materially are discussed in the Company’s filings with the Securities and Exchange Commission, including the risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 24, 2026, as amended on April 30, 2026. Forward-looking statements speak only as of the date of this press release, and the Company assumes no obligation to update them except as required by law.

Investors Contact
IR@blaize.com

Media Contact
press@blaize.com

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $52.5 million of shares of the Company’s common stock offered in the public offering under the same terms and conditions. The offering is expected to close on or about October 7, 2026, subject to satisfaction of customary closing conditions.

Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the offering. LifeSci Capital is acting as passive bookrunner for the offering.

Spyre intends to use the net proceeds from the proposed public offering to continue to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including to fund preclinical studies, clinical trials, manufacturing, and Phase 3 readiness, as well as a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Any remaining proceeds will be used for other ongoing research and development, working capital and other general corporate purposes.

A registration statement on Form S-3 (File No. 333-297063) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on June 26, 2026. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting a4p7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

Safe Harbor / Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding Spyre’s expectations regarding the consummation of the offering and the satisfaction of customary closing conditions related to the offering. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect,” the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, market conditions and satisfaction of customary closing conditions related to the offering, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s ongoing or planned clinical trials for its product candidates; the Company’s ability to elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the previously disclosed data reported for the Company’s programs; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between the United States and Iran, Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on the Company’s operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact the Company’s business operations, including restricting international trade by the United States, China or other countries; and those risks described in the Company’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q, as well as in other filings and reports that the Company makes from time to time with the SEC. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for the Company’s management to predict all risks, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The Company undertakes no obligation to update publicly any forward-looking statement for any reason after the date of this press release to conform these statements to actual results, to reflect changes in the Company’s expectations, or otherwise, except as required by law.

For Investors:
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

For Media:
Josie Butler, 1AB
josie@1abmedia.com

WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) — Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced the pricing of its previously announced underwritten public offering of 4,117,648 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to the Company from this offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional approximately $52.5 million of shares of the Company’s common stock offered in the public offering under the same terms and conditions. The offering is expected to close on or about October 7, 2026, subject to satisfaction of customary closing conditions.

Jefferies, TD Cowen, Leerink Partners and Stifel are acting as the joint book-running managers for the offering. LifeSci Capital is acting as passive bookrunner for the offering.

Spyre intends to use the net proceeds from the proposed public offering to continue to advance its programs in Gastroenterology, Rheumatology, and Dermatology, including to fund preclinical studies, clinical trials, manufacturing, and Phase 3 readiness, as well as a new program to advance SPY072 into late-stage development for hidradenitis suppurativa. Any remaining proceeds will be used for other ongoing research and development, working capital and other general corporate purposes.

A registration statement on Form S-3 (File No. 333-297063) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on June 26, 2026. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105, or by email at syndicate@leerink.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre’s pipeline includes investigational extended half-life antibodies targeting a4p7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

Safe Harbor / Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding Spyre’s expectations regarding the consummation of the offering and the satisfaction of customary closing conditions related to the offering. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect,” the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, market conditions and satisfaction of customary closing conditions related to the offering, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s ongoing or planned clinical trials for its product candidates; the Company’s ability to elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients; the potential for interim data not being delivered within expected time frames or final data not being consistent with or different than the previously disclosed data reported for the Company’s programs; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between the United States and Iran, Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on the Company’s operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact the Company’s business operations, including restricting international trade by the United States, China or other countries; and those risks described in the Company’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q, as well as in other filings and reports that the Company makes from time to time with the SEC. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for the Company’s management to predict all risks, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The Company undertakes no obligation to update publicly any forward-looking statement for any reason after the date of this press release to conform these statements to actual results, to reflect changes in the Company’s expectations, or otherwise, except as required by law.

For Investors:
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
Eric.mcintyre@spyre.com

For Media:
Josie Butler, 1AB
josie@1abmedia.com

MARLBOROUGH, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) — IPG Photonics today announced that from October 6^th though October 8^th, 2026, IPG Defense will participate in Land Forces 2026 in Perth, Australia to showcase CROSSBOW™ High-Energy Laser (HEL) Systems. This key industry event provides a platform to forge strategic alliances and collaborate to shape the future of the global aerospace and defense market.

IPG Defense Products at Land Forces 2026

In the IPG Defense booth, visitors will experience both the previously released CROSSBOW MINI and the first addition to the new CROSSBOW SE product line, the CROSSBOW SE1 8 kW. Multiple systems will be on display in a typical layered defense arrangement to showcase several deployment scenarios first-hand. Both products share the same scalable architecture and easily integrate with available radar and C2 systems. CROSSBOW MINI systems allow for rapid expeditionary deployment where mobility is critical, and the CROSSBOW SE product line provides increased laser power options for longer range defense against Group I-III UAS threats.

In addition, interactive kiosks will allow attendees to conduct virtual simulations by placing UAS threats and CROSSBOW laser defense systems into scenes to defend critical assets. This interactive experience provides a detailed example of how IPG Defense products can be deployed to defend against UAS swarms in any environment.

Increased Drone Incursions are Fueling Demand

Military installations, government buildings, public arenas, port complexes and critical infrastructures are but a few of the locations where CROSSBOW laser defense systems provide scalable and cost-effective Counter-UAS protection.

“Across the globe, UAS, whether individually or in swarms, continue to threaten both military and civilian critical assets,” said Dr. Ben Allison, Vice President of IPG Defense. “Our presence here at Land Forces is to engage with customers and showcase how our current product lines address their needs, with particular emphasis on demonstrating cooperative engagements with multiple CROSSBOW systems in a layered defense architecture.”

The IPG Defense booth K05 on Level 3 at Land Forces will be staffed with knowledgeable program personnel who are able to discuss laser defense solutions and IPG Defense products.

For more information please visit: IPGDefense.com

About Land Forces

Held biennially over three days, Land Forces is Australia’s premier platform for advancing land-based defense capability as a platform for engagement, featuring a comprehensive international industry exhibition, a specialist conference program with presentations and symposia from leading defense institutions, and extensive networking opportunities.

As the land domain continues to evolve through investment, and strategic partnerships, Land Forces provides a vital interface for stakeholders to explore capability development, supply chain integration, and future force design.

About IPG Defense

IPG Defense is delivering scalable and cost-effective laser Counter-UAS systems for protection of commercial, government and military critical assets and sites from UAS threats.

About IPG Photonics

Innovation is at the heart of IPG Photonics. As a global leader in laser technology, we apply light to transform the world. From manufacturing to medical and beyond, our breakthrough laser solutions power our customers’ success and expand what’s possible.

Contact
Dr. Ben Allison
VP, IPG Defense Products
+1 256-715-5750
ballison@IPGDefense.com

MARLBOROUGH, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) — IPG Photonics today announced that from October 6^th though October 8^th, 2026, IPG Defense will participate in Land Forces 2026 in Perth, Australia to showcase CROSSBOW™ High-Energy Laser (HEL) Systems. This key industry event provides a platform to forge strategic alliances and collaborate to shape the future of the global aerospace and defense market.

IPG Defense Products at Land Forces 2026

In the IPG Defense booth, visitors will experience both the previously released CROSSBOW MINI and the first addition to the new CROSSBOW SE product line, the CROSSBOW SE1 8 kW. Multiple systems will be on display in a typical layered defense arrangement to showcase several deployment scenarios first-hand. Both products share the same scalable architecture and easily integrate with available radar and C2 systems. CROSSBOW MINI systems allow for rapid expeditionary deployment where mobility is critical, and the CROSSBOW SE product line provides increased laser power options for longer range defense against Group I-III UAS threats.

In addition, interactive kiosks will allow attendees to conduct virtual simulations by placing UAS threats and CROSSBOW laser defense systems into scenes to defend critical assets. This interactive experience provides a detailed example of how IPG Defense products can be deployed to defend against UAS swarms in any environment.

Increased Drone Incursions are Fueling Demand

Military installations, government buildings, public arenas, port complexes and critical infrastructures are but a few of the locations where CROSSBOW laser defense systems provide scalable and cost-effective Counter-UAS protection.

“Across the globe, UAS, whether individually or in swarms, continue to threaten both military and civilian critical assets,” said Dr. Ben Allison, Vice President of IPG Defense. “Our presence here at Land Forces is to engage with customers and showcase how our current product lines address their needs, with particular emphasis on demonstrating cooperative engagements with multiple CROSSBOW systems in a layered defense architecture.”

The IPG Defense booth K05 on Level 3 at Land Forces will be staffed with knowledgeable program personnel who are able to discuss laser defense solutions and IPG Defense products.

For more information please visit: IPGDefense.com

About Land Forces

Held biennially over three days, Land Forces is Australia’s premier platform for advancing land-based defense capability as a platform for engagement, featuring a comprehensive international industry exhibition, a specialist conference program with presentations and symposia from leading defense institutions, and extensive networking opportunities.

As the land domain continues to evolve through investment, and strategic partnerships, Land Forces provides a vital interface for stakeholders to explore capability development, supply chain integration, and future force design.

About IPG Defense

IPG Defense is delivering scalable and cost-effective laser Counter-UAS systems for protection of commercial, government and military critical assets and sites from UAS threats.

About IPG Photonics

Innovation is at the heart of IPG Photonics. As a global leader in laser technology, we apply light to transform the world. From manufacturing to medical and beyond, our breakthrough laser solutions power our customers’ success and expand what’s possible.

Contact
Dr. Ben Allison
VP, IPG Defense Products
+1 256-715-5750
ballison@IPGDefense.com

THE WOODLANDS, Texas, Oct. 05, 2026 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 386 homes in September 2026, including 8 currently or previously leased single-family rental homes. This represents a 9.0% increase compared to 354 homes closed in September 2025. Additionally, the Company closed 1,222 homes during the third quarter of 2026, including 33 currently or previously leased single-family rental homes. This represents a 10.4% increase compared to 1,107 homes closed in the third quarter of 2025.

As of September 30, 2026, the Company had 151 active selling communities.

The Company plans to release financial results for the third quarter ended September 30, 2026 before the market opens on Tuesday, November 3, 2026. The Company will hold a conference call at 12:30 p.m. Eastern Time on the same day to discuss the results.

A link to the live audio webcast will be provided through the Investor Relations page of the Company’s website at www.investor.lgihomes.com under the Events and Presentations section.

An archive of the webcast will be available for replay on the Company’s website for one year from the date of the conference call.

About LGI Homes, Inc.

Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. LGI Homes has closed over 80,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek’s list of the World’s Most Trustworthy Companies. LGI Homes’ commitment to excellence extends to its employees, earning the Company numerous workplace awards at the local, state, and national level, including the Top Workplaces USA 2026 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company’s website at www.lgihomes.com.

CONTACT:
Joshua D. Fattor
Executive Vice President of Finance and Capital Markets
Head of Investor Relations
(281) 210-2586
investorrelations@lgihomes.com

THE WOODLANDS, Texas, Oct. 05, 2026 (GLOBE NEWSWIRE) — LGI Homes, Inc. (NASDAQ: LGIH) today announced it closed 386 homes in September 2026, including 8 currently or previously leased single-family rental homes. This represents a 9.0% increase compared to 354 homes closed in September 2025. Additionally, the Company closed 1,222 homes during the third quarter of 2026, including 33 currently or previously leased single-family rental homes. This represents a 10.4% increase compared to 1,107 homes closed in the third quarter of 2025.

As of September 30, 2026, the Company had 151 active selling communities.

The Company plans to release financial results for the third quarter ended September 30, 2026 before the market opens on Tuesday, November 3, 2026. The Company will hold a conference call at 12:30 p.m. Eastern Time on the same day to discuss the results.

A link to the live audio webcast will be provided through the Investor Relations page of the Company’s website at www.investor.lgihomes.com under the Events and Presentations section.

An archive of the webcast will be available for replay on the Company’s website for one year from the date of the conference call.

About LGI Homes, Inc.

Headquartered in The Woodlands, Texas, LGI Homes, Inc. is a pioneer in the homebuilding industry, successfully applying an innovative and systematic approach to the design, construction and sale of homes across 36 markets in 21 states. LGI Homes has closed over 80,000 homes since its founding in 2003 and has delivered profitable financial results every year. Nationally recognized for its quality construction and exceptional customer service, LGI Homes was named to Newsweek’s list of the World’s Most Trustworthy Companies. LGI Homes’ commitment to excellence extends to its employees, earning the Company numerous workplace awards at the local, state, and national level, including the Top Workplaces USA 2026 Award. For more information about LGI Homes and its unique operating model focused on making the dream of homeownership a reality for families across the nation, please visit the Company’s website at www.lgihomes.com.

CONTACT:
Joshua D. Fattor
Executive Vice President of Finance and Capital Markets
Head of Investor Relations
(281) 210-2586
investorrelations@lgihomes.com